Table 3.
Onset of blood smear and Plasmodium 18S rRNA positivity and treatment for blood smear–positive participants
| Days from CHMI to | Statistic | MC-001 (N = 6) | MC-003 infectivity and drug controls (N = 11) | MC-003 vaccinated (N = 14) | PfSPZ-Cvac PYR (N = 6) | All studies (N = 37) |
|---|---|---|---|---|---|---|
| Biomarker positive including low positives of ≥ 10 est. parasites/mL | Mean | 7.7 | 6.9 | 7.5 | 9.2 | 7.6 |
| 95% CI | 6.4–8.9 | 6.7–7.1 | 6.9–8.1 | 6.1–12.2 | 7.1–8.1 | |
| Biomarker ≥ 20 est. parasites/mL | Mean | 7.7 | 7.0 | 7.7 | 9.3 | 7.8 |
| 95% CI | 6.4–8.9 | 7.0–7.0 | 6.9–8.6 | 6.4–12.3 | 7.2–8.3 | |
| Biomarker ≥ 100 est. parasites/mL | Mean | 8.2 | 7.0 | 8.2 | 10.8 | 8.3 |
| 95% CI | 6.8–9.6 | 7.0–7.0 | 7.3–9.1 | 7.2–14.4 | 7.6–9.0 | |
| Biomarker ≥ 250 est. parasites/mL | Mean | 9.0 | 7.3 | 8.7 | 11.7 | 8.8 |
| 95% CI | 7.3–10.8 | 6.8–7.7 | 7.9–9.6 | 8.6–14.7 | 8.1–9.5 | |
| Biomarker ≥ 500 est. parasites/mL | Mean | 9.3 | 7.5 | 9.0 | 12.2 | 9.1 |
| 95% CI | 7.4–11.3 | 6.9–8.0 | 8.0–10.0 | 9.7–14.7 | 8.4–9.9 | |
| Biomarker ≥ 1,000 est. parasites/mL | Mean | 9.8 | 7.8 | 9.8 | 12.2 | 9.6 |
| 95% CI | 8.0–11.6 | 7.1–8.5 | 8.6–11.0 | 9.7–14.7 | 8.8–10.3 | |
| Biomarker ≥ 10,000 est. parasites/mL | Mean | 11.2* | 9.0* | 11.0* | 12.6* | 10.7* |
| 95% CI | 9.0–13.4 | 7.9–10.1 | 9.7–12.7 | 11.2–14.0 | 10.0–11.5 | |
| Positive blood smear | Mean | 11.2 | 9.2 | 11.4 | 13.5 | 11.0 |
| 95% CI | 9.5–12.9 | 8.4–10.0 | 10.0–12.7 | 11.0–16.0 | 10.3–11.8 | |
| Treatment | Mean | 11.2 | 9.2 | 11.4 | 13.3 | 11.0 |
| 95% CI | 9.5–12.9 | 8.4–10.0 | 10.0–12.7 | 10.8–15.9 | 10.2–11.8 |
CHMI = controlled human malaria infection; PYR = pyrimethamine.
* Fewer than the total number of participants reached a biomarker-calculated density of 10,000 estimated parasites/mL before treatment (MC-001”, n = 5; MC-003 infectivity/drug controls, n = 9; MC-003 vaccinated, n = 12; PfSPZ-Cvac PYR, n = 5; total n = 31).